```markdown
---
application_number: "213426Orig1s000"
applicant_name: "Esteve Pharmaceuticals, S.A."
us_agent: 
  name: "Rebecca Nortz"
  organization: "Esteve Pharmaceuticals, LLC"
  address: 
    street: "909 Davis Street, Suite 500"
    city: "Evanston"
    state: "IL"
    zip: "60201"
contact:
  name: "Jaimin Patel"
  role: "Regulatory Project Manager"
  phone: "(301) 796-0412"
director:
  name: "Rigoberto Roca, MD"
  title: "Acting Director, Division of Anesthesiology, Addiction Medicine, and Pain Medicine"
  office: "Office of Neuroscience"
  center: "Center for Drug Evaluation and Research"
proprietary_name: "Seglentis"
initial_submission_date: "2019-05-15"
major_amendment_date: "2020-03-02"
letter_date: "2020-06-15"
product: "Celecoxib and Tramadol Hydrochloride Tablets"
submission_type: "505(b)(2)"
status: "Complete Response - Not Approvable in Current Form"
inspection_status: "Not ready for inspection"
proposed_rems: true
enclosures:
  - Labeling
  - Medication Guide
---

## Critical Data

| Field                        | Value                                                                 |
|-----------------------------|-----------------------------------------------------------------------|
| Application Number          | 213426Orig1s000                                                       |
| Applicant                   | Esteve Pharmaceuticals, S.A.                                         |
| US Agent                    | Rebecca Nortz (Esteve Pharmaceuticals, LLC)                          |
| Proprietary Name            | Seglentis (conditionally accepted)                                   |
| Product                     | Celecoxib and Tramadol Hydrochloride Tablets                         |
| Submission Type             | 505(b)(2)                                                             |
| Initial NDA Submission      | May 15, 2019                                                          |
| Major Amendment             | March 2, 2020                                                         |
| Status                      | Complete Response – Not Approvable in Current Form                   |
| Inspection Outcome          | Incomplete; facility not ready                                       |
| REMS Required               | Yes                                                                   |
| Safety Update Required      | Yes                                                                   |
| Response Deadline           | Within 1 year of letter (21 CFR 314.110)                             |
| Contact (Regulatory PM)     | Jaimin Patel - (301) 796-0412                                        |
| Acting Director             | Rigoberto Roca, MD                                                   |
| Letter Date                 | June 15, 2020                                                         |
| Enclosures                  | Labeling, Medication Guide                                           |

---

# CENTER FOR DRUG EVALUATION AND RESEARCH  
## APPLICATION NUMBER: 213426Orig1s000  
## OTHER ACTION LETTERS  

### NDA 213426  
### COMPLETE RESPONSE  

Esteve Pharmaceuticals, S.A.  
c/o Esteve Pharmaceuticals, LLC  
909 Davis Street, Suite 500  
Evanston, IL 60201  
Attention: Rebecca Nortz  
US Agent for Esteve Pharmaceuticals, S.A.

---

Please refer to your new drug application (NDA) dated and received May 15, 2019, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for celecoxib and tramadol hydrochloride tablets.

We acknowledge receipt of your major amendment dated March 2, 2020, which extended the goal date by three months.

We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form. We have described our reasons for this action below and, where possible, our recommendations to address these issues.

---

## FACILITY INSPECTIONS

1. Our field investigator could not complete inspection of the manufacturing facility because the facility was not ready for inspection.

**Information needed to resolve deficiency:**  
Satisfactory inspection is required before this application may be approved.  
Please notify us in writing when this facility is ready for inspection.

---

## PRESCRIBING INFORMATION

Your proposed Prescribing Information (PI) must conform to the content and format regulations found at 21 CFR 201.56(a) and (d) and 201.57.

### Labeling Review Resources

We encourage you to review the labeling review resources on the following:

- The Final Rule (Physician Labeling Rule) on the content and format of the PI for human drug and biological products  
- The Final Rule (Pregnancy and Lactation Labeling Rule)  
- Regulations and related guidance documents  
- A sample tool illustrating the format for Highlights and Contents  
- The Selected Requirements for Prescribing Information (SRPI) − a checklist of important format items  
- FDA’s established pharmacologic class (EPC) text phrases for inclusion in the Highlights Indications and Usage heading  

We refer to the draft labeling and medication guide received via email on June 12, 2020, and March 12, 2020, respectively, which incorporated our requested revisions. We reserve additional comments until the application is otherwise adequate.

Resubmit the revised draft labeling and medication guide with your complete response submission.

- Use the SRPI checklist to correct formatting errors.  
- Submit updated content of labeling [21 CFR 314.50(l)(1)(i)] in structured product labeling (SPL) format.

Provide:

- A highlighted or marked-up copy  
- A clean Word version  
- The marked-up copy should include annotations that support any proposed changes.

---

## PROPRIETARY NAME

Refer to correspondence dated April 7, 2020, addressing the proposed proprietary name, Seglentis. The name was found acceptable pending application approval.  
Please resubmit the proposed proprietary name in your response to the application deficiencies.

---

## RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS

Under section 505-1 of the FDCA:

- FDA may require a REMS if necessary to ensure that the drug's benefits outweigh the risks.

We acknowledge receipt of your proposed REMS submitted May 15, 2019, including:

- A Medication Guide  
- Elements to assure safe use  
- An implementation system  
- A timetable for submission of assessments  

We agree that a REMS will be necessary for celecoxib and tramadol hydrochloride tablets to address risks of:

- Addiction  
- Unintentional overdose  
- Death due to inappropriate prescribing, abuse, and misuse

**Administrative Instructions:**

- Designate all submissions related to this REMS as:  
  `PROPOSED REMS for NDA 213426-AMENDMENT`
- Submit proposed REMS materials in Microsoft Word format; PDFs are acceptable for forms/screenshots if necessary.

---

## SAFETY UPDATE

When responding to deficiencies, include a safety update under 21 CFR 314.50(d)(5)(vi)(b):

1. Describe in detail any significant changes or findings in the safety profile.

2. For discontinuations due to adverse events, serious adverse events, and common adverse events:  
    - Present new safety data in the same format as in the original submission.  
    - Provide tabulations of new and original data.  
    - Include comparative tables of adverse event frequencies.  
    - Provide separate tables for other indications.

3. Retabulate premature discontinuation reasons using new trial data. Highlight new trends or patterns.

4. Provide:
    - Case report forms and narrative summaries for patients who died or discontinued due to adverse events  
    - Narrative summaries for serious adverse events

5. Describe information indicating any substantial change in common but less serious events.

6. Provide updated exposure data (number of subjects, person time).

7. Provide a summary of worldwide post-marketing safety experience including updated use estimates.

8. Provide English translations of current approved foreign labeling not previously submitted.

---

## ADDITIONAL COMMENTS

The following are not approvability issues but must be addressed in your complete response:

Although you state a literature search was conducted to support PLLR labeling, you did not identify articles or provide synopses supporting your conclusion.

FDA identified several articles which should be reviewed:

a. Aboulhoda BE, Hassan SS. (2018)  
b. Abdellatief RB, Elgamal DA, Mohamed EEM. (2015)  
c. Attia AM, Bakry OA, Yassin H, et al. (2018)  
d. Ghoneim FM, Khalaf HA, et al. (2014)  
e. Winnall WR, Muir JA, Liew S, et al. (2009)  
f. Selmanoglu G, Kockaya EA, Akay MT, et al. (2006)  
g. Olliges A., Wimmer S., Nusing R.M. (2011)  
h. Nagano A., Arioka M., Takahashi-Yanaga F., et al. (2017)

With your resubmission, provide summaries of nonclinical literature for tramadol or celecoxib that may inform on:

- Pregnancy  
- Lactation  
- Female and male fertility  

Discuss whether such information should be included in labeling.

---

## OTHER

You must respond or resubmit within one year of this letter (21 CFR 314.110). If you do not, FDA may consider your application withdrawn under 21 CFR 314.65.

A resubmission:

- Must fully address all deficiencies  
- Mark with "RESUBMISSION" in large, bold font in the cover letter  
- Must be considered complete. Partial responses will not be processed as resubmissions

You may request a meeting or teleconference to discuss next steps. Submit your meeting request per the draft guidance for industry:  
"Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products."

The drug product may not be marketed before receiving written approval.

---

If you have any questions, contact:

**Jaimin Patel**  
Regulatory Project Manager  
(301) 796-0412

Sincerely,  
**Rigoberto Roca, MD**  
Acting Director  
Division of Anesthesiology, Addiction Medicine, and Pain Medicine  
Office of Neuroscience  
Center for Drug Evaluation and Research

---

### ENCLOSURE(S):

- Labeling  
- Medication Guide

---

This is a representation of an electronic record that was signed electronically.  
Following this are manifestations of any and all electronic signatures for this record.

---

/s/  
**RIGOBERTO A ROCA**  
06/15/2020 08:51:49 AM
```